NurExone Biologic is developing a revolutionary biological Extracellular Vesicles (EVs)-based technology drug platform to provide functional recovery from damage in the central nervous system (CNS).
According to the National Cancer Institute (NCI), exosomes which look like tiny sacs approximately 30 to 150 nm in diameter are formed inside a cell and contain some of the cell’s proteins, DNA, and RNA.
“Currently, no available treatment technologies has all four of our product’s properties – potential to repair full transection, non-immunogenic, off-the-shelf use, and non-invasive,” said CEO Dr. Lior Shaltiel, PhD